ImmunoScape: Funding, Investors & Team (Sep 2026)
ImmunoScape is a company focused on immunomics, using a technology platform to analyze and characterize the human immune response in great detail. The Deep Immunomics platform combines various advanced techniques to provide novel and reliable immune profiling information. This technology is used in various medical fields, particularly in oncology and infectious disease, to improve understanding of immunotherapy effectiveness and safety, as well as to discover potential drug targets.
ImmunoScape has raised $28.3M across 4 funding rounds on record, the most recent an undisclosed round announced in Mar 2026.
ImmunoScape Company Profile and Key Stats
Latest funding round on record: Mar 2026.
ImmunoScape Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
ImmunoScape raised $14.0M in an undisclosed round announced in Apr 2021.
1.4 years later, an undisclosed round of $14.0M was announced in Sep 2022.
2 years later, an undisclosed round of $250k was announced in Sep 2024.
1.5 years later, an undisclosed round was announced in Mar 2026 with no disclosed amount.
ImmunoScape Founders and Leadership Team
Contact details for the ImmunoScape team: 2 of 4 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →ImmunoScape Funding Compared to Other Biotechnology Startups
Funded Startups Like ImmunoScape in Biotechnology and Singapore
Companies Similar to ImmunoScape
YouLabs is an early-stage, data-driven biotechnology and longevity technology company focused on shifting…
Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based…
Nuevocor, which has locations in both the United States and Singapore, is working on creating genetic…
Aevice Health Pte Ltd is a Singaporean company that originated from Nanyang Technological University and…
Mirxes is a biotech firm focused on uncovering, advancing, and providing precise preventive healthcare…
BioDefense introduces Bioshield, a product derived from edible ingredients designed to safeguard your food by…
Auristone delivers practical clinical insights through our epigenomics workflows, providing actionable…
ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in…
GDMC is a pharmaceutical organization that specializes in the production and development of genetic…
Meatiply, a company focused on food research, specializes in the creation and manufacturing of meat…
Empowering Healthier Meals by Harnessing the Best from Nature and Combining that our Knowledge of Food…
Automera dedicates itself to the creation of innovative therapeutic approaches for drug development.
ImmunoScape Funding FAQs
What does ImmunoScape do?
ImmunoScape is a company focused on immunomics, using a technology platform to analyze and characterize the human immune response in great detail. The Deep Immunomics platform combines various advanced techniques to provide novel and reliable immune profiling information. This technology is used in various medical fields, particularly in oncology and infectious disease, to improve understanding of immunotherapy effectiveness and safety, as well as to discover potential drug targets.
How much funding has ImmunoScape raised?
ImmunoScape has raised $28.3M across 4 rounds on record.
When did ImmunoScape last raise funding?
ImmunoScape's most recent funding round on record was announced in Mar 2026. The amount was not disclosed.
Who founded ImmunoScape?
FundedIQ lists Alessandra Nardin (Founder), Michael Fehlings (Founder) at ImmunoScape.
Who is the CEO of ImmunoScape?
Choon Ng is listed as CEO at ImmunoScape.
Where is ImmunoScape headquartered?
ImmunoScape is based in Singapore, Central Region, Singapore.
How many employees does ImmunoScape have?
ImmunoScape is in the 11-50 employee band.
About FundedIQ's ImmunoScape Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImmunoScape is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.